Evidence map›Paper›PMID 37649085›Full record

ArticleCancer immunology research2023

Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function.

Caimei Zhang, Siddhant Kadu, Yansen Xiao, Omar Johnson, Andre Kelly, Roddy S O'Connor, Meizan Lai, Hong Kong, Sriram Srivatsa, Victoria Tai and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Innate immune cells in chimeric antigen receptor therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Caimei ZhangCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0006-1217-9919
Siddhant KaduCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0000-3616-5243
Yansen XiaoCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0009-9135-1335
Omar JohnsonCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-7644-9064
Andre KellyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0000-6104-6107
Roddy S O'ConnorCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-5645-4544
Meizan LaiCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0007-6389-1241
Hong KongCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0002-5851-1121
Sriram SrivatsaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-2267-3447
Victoria TaiCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0009-0003-7284-6187
Eli GreenblattIsoPlexis, Branford, Connecticut.ORCID 0009-0008-9258-3579
Matthew HolmesIsoPlexis, Branford, Connecticut.ORCID 0009-0009-4762-6151
James L RileyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-1057-576X
Carl H JuneCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0003-0241-3557
Neil C SheppardCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-9551-9491
University of Pennsylvania · USIsoPlexis (United States) · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
Directing the metabolic fate of CAR T cellsR01CA226983 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H. · 2018 to 2022
$2.1M
NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA226983NIAID NIH HHS P30 AI045008
6 · The paper itself

Abstract

Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder cells expressing a core transgene set of membrane-bound (mb) IL15 and/or mbIL21 together with 41BBL. Prior comparisons of mbIL15 to mbIL21 for NK expansion lack comparisons of key attributes of the resulting NK cells, including their high-dimensional phenotype, polyfunctionality, the breadth and potency of cytotoxicity, cellular metabolism, and activity in xenograft tumor models. Moreover, despite multiple rounds of K562 stimulation, studies of sequential use of mbIL15- and mbIL21-based feeder cells are absent. We addressed these gaps and found that using mbIL15- versus mbIL21-based feeder cells drove distinct phenotypic and functional profiles. Feeder cells expressing mbIL15 alone drove superior functionality by nearly all measures, whereas those expressing mbIL21 alone drove superior yield. In combination, most attributes resembled those imparted by mbIL21, whereas in sequence, NK yield approximated that imparted by the first cytokine, and the phenotype, transcriptome, and function resembled that driven by the second cytokine, highlighting the plasticity of NK cell differentiation. The sequence mbIL21 followed by mbIL15 was advantageous in achieving significant yields of highly functional NK cells that demonstrated equivalent in vivo activity to those expanded by mbIL15 alone in two of three xenograft models. Our findings define the impact of mbIL15 versus mbIL21 during NK expansion and reveal a previously underappreciated tradeoff between NK yield and function for which sequential use of mbIL21-based followed by mbIL15-based feeder cells may be the optimal approach in many settings.

Indexed as

Interleukin-15Killer Cells, NaturalCell ProliferationCytokinesHumansInterleukin-21K562 CellsCytokinesInterleukin-15Interleukin-21

Identifiers

PMID37649085
PMCPMC10618651
OpenAlexW4386305355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.